SIRPA and neoplasm: Moreover, it was shown that RRx-001 induces a surface decrease of CD47 on tumor cells and SIRP-α blocking on macrophages and a reduction of the phagocytosis inhibitory effect of the CD47/SIRP-α pathway that leads to a decrease in tumor mass, involving a shift from M2 macrophage to the more anti-tumor M1 phenotype [76,77,78,79,80].